急性骨髄性白血病における測定可能な残留病導治療: 実践的な洞察
Boaz Nachmias1, Arnon Haran1, Meira Yisraeli Salman2
1Leukemia Service, Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
British journal of haematology
|August 31, 2025
まとめ
測定可能な残留疾患 (MRD) のモニタリングは,急性骨髄性白血病 (AML) の治療に不可欠です. このレビューでは,MRD
科学分野:
- 血液学
- 腫瘍学
- 分子診断
背景:
- 測定可能な残留疾患 (MRD) は,急性骨髄性白血病 (AML) の主要な予後指標である.
- MRDの正確な評価は,患者のアウトカムを予測し,治療の調整を導くために不可欠です.
研究 の 目的:
- 様々なAML遺伝子のサブグループにおけるMRDの予後的意義を見直す.
- 予防療法,幹細胞移植,維持戦略を含む治療決定におけるMRDの役割を評価する.
主な方法:
- AMLのMRD評価における最近の研究と新興傾向の批判的評価
- 治療戦略と臨床意思決定に対するMRDの影響の分析
主要な成果:
- MRDは様々なAML遺伝子プロファイルで 予後値を持っています
- MRDは予防的な治療と幹細胞移植に関する決定に影響を与えるという証拠がある.
結論:
- MRDは,AML管理の意思決定ツールとして進化しています.
- さらにランダム化試験は,MRDによる治療プロトコルを固め,パーソナライズされたケアを最適化するために必要である.
さらに関連する動画
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.1K
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
261
関連する概念動画
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...